Clearside Biomedical to Participate in Two Upcoming Investor Conferences in June 2021
June 09 2021 - 7:05AM
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical
company dedicated to developing and delivering treatments that
restore and preserve vision for people with serious back of the eye
diseases, announced today that George Lasezkay, Pharm.D., J.D.,
President and Chief Executive Officer, and Thomas A. Ciulla, M.D.,
MBA, Chief Medical Officer and Chief Development Officer, will
participate in two upcoming investor conferences in June 2021:
JMP Securities Life Sciences ConferenceFireside
ChatWednesday, June 16, 2021 at 1:00 pm ET
Raymond James Human Health Innovations
ConferenceFireside ChatWednesday, June 23, 2021 at 8:40 am ET
A link to the live and archived webcasts may be
accessed on the Clearside website under the Investors section:
Events and Presentations. An archive of the webcast will be
available for three months.
About Clearside Biomedical
Clearside Biomedical, Inc. is a
biopharmaceutical company dedicated to developing and delivering
treatments that restore and preserve vision for people with serious
back of the eye diseases. Clearside’s proprietary SCS
Microinjector® targets the suprachoroidal space (SCS®) and offers
unique access to the macula, retina and choroid where
sight-threatening disease often occurs. The Company’s SCS injection
platform is an inherently flexible, in-office, non-surgical
procedure, intended to provide targeted delivery to the site of
disease and to work with both established and new formulations of
medications. For more information, please visit
www.clearsidebio.com.
Investor and Media Contacts:Jenny Kobin Remy
Bernarda ir@clearsidebio.com(678) 430-8206
Source: Clearside Biomedical, Inc.
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Apr 2023 to Apr 2024